Maha Ayyoub

List of Publications by Year
in descending order

92 papers	5,380 citations	101384 36 h-index	85405 71 g-index
94 all docs	94 docs citations	94 times ranked	8548 citing authors

#	Article	IF	Citations
1	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
2	Microbiome and Anticancer Immunosurveillance. Cell, 2016, 165, 276-287.	13.5	366
3	Human memory FOXP3⁺Tregs secrete IL-17 ex vivo and constitutively express the T_H17 lineage-specific transcription factor RORÎ³t. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8635-8640.	3.3	282
4	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8947-8952.	3.3	275
5	A peripheral circulating compartment of natural naive CD4+ Tregs. Journal of Clinical Investigation, 2005, 115, 1953-1962.	3.9	261
6	Cross-reactivity between tumor MHC class Iâ€“restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	6.0	217
7	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14453-14458.	3.3	202
8	Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells. Journal of Immunology, 2006, 177, 944-949.	0.4	175
9	Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications, 2017, 8, 592.	5.8	166
10	IL-1Î² and IL-2 convert human Treg into TH17 cells. Clinical Immunology, 2009, 131, 298-307.	1.4	151
11	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunological Reviews, 2002, 188, 81-96.	2.8	146
12	Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenaseâ€“Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 5498-5504.	0.4	140
13	Human RORÎ³t ⁺ T _H 17 cells preferentially differentiate from naive FOXP3 ⁺ Treg in the presence of lineage-specific polarizing factors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19402-19407.	3.3	135
14	CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity. Cancer Research, 2012, 72, 4351-4360.	0.4	125
15	Immunological off-target effects of imatinib. Nature Reviews Clinical Oncology, 2016, 13, 431-446.	12.5	120
16	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
17	Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma. Journal of Immunology, 2002, 168, 1717-1722.	0.4	106
18	CpG-A and CpG-B oligonucleotides differentially enhance human peptideâ€“specific primary and memory CD8+ T-cell responses in vitro. Blood, 2004, 103, 2162-2169.	0.6	94

#	Article	IF	Citations
19	Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity, 2020, 53, 824-839.e10.	6.6	85
20	The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector Î±Î² T Cells. Journal of Immunology, 2001, 167, 6165-6170.	0.4	82
21	Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. European Journal of Immunology, 2001, 31, 2642-2651.	1.6	76
22	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight, 2021, 6, .	2.3	64
23	Processing of Tumor-Associated Antigen by the Proteasomes of Dendritic Cells Controls In vivo T-Cell Responses. Cancer Research, 2006, 66, 5461-5468.	0.4	60
24	Interleukin 2-mediated Conversion of Ovarian Cancer-associated CD4+ Regulatory T Cells Into Proinflammatory Interleukin 17-producing Helper T Cells. Journal of Immunotherapy, 2009, 32, 101-108.	1.2	58
25	Human Memory Heliosâ˜ FOXP3+ Regulatory T Cells (Tregs) Encompass Induced Tregs That Express Aiolos and Respond to IL-1Î² by Downregulating Their Suppressor Functions. Journal of Immunology, 2013, 191, 4619-4627.	0.4	58
26	Distinct Structural TCR Repertoires in Naturally Occurring Versus Vaccine-Induced CD8+ T-Cell Responses to the Tumor-Specific Antigen NY-ESO-1. Journal of Immunotherapy, 2005, 28, 252-257.	1.2	56
27	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research, 2021, 27, 1037-1047.	3.2	55
28	The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immunity, 2004, 4, 7.	3.2	50
29	Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clinical Immunology, 2008, 126, 291-302.	1.4	46
30	A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy. Journal of Immunology, 2001, 167, 5852-5861.	0.4	44
31	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15RÎ± and NKG2D Triggering. Cancer Research, 2014, 74, 68-80.	0.4	43
32	Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Reports, 2019, 26, 94-107.e7.	2.9	42
33	Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Research, 2003, 63, 5601-6.	0.4	40
34	Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic Tâ€„lymphocytes of unknown specificity. European Journal of Immunology, 2002, 32, 2292.	1.6	37
35	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clinical Cancer Research, 2003, 9, 669-77.	3.2	37
36	Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunity, 2004, 4, 4.	3.2	36

#	Article	IF	Citations
37	Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7437-7442.	3.3	35
38	Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival. Journal of Immunotherapy, 2014, 37, 73-76.	1.2	35
39	Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-Î³â€"Secreting Cells as They Differentiate into Effector T Cells <i>In Vivo</i>. Cancer Research, 2012, 72, 1059-1063.	0.4	33
40	Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells. Clinical Cancer Research, 2006, 12, 398-404.	3.2	32
41	Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content. Journal of Clinical Immunology, 2006, 26, 447-456.	2.0	31
42	Ex Vivo IL-1 Receptor Type I Expression in Human CD4+ T Cells Identifies an Early Intermediate in the Differentiation of Th17 from FOXP3+ Naive Regulatory T Cells. Journal of Immunology, 2011, 187, 5196-5202.	0.4	31
43	Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos⁺, but not natural Helios⁺, FOXP3⁺ Treg cells. European Journal of Immunology, 2015, 45, 474-479.	1.6	29
44	Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immunity, 2003, 3, 15.	3.2	29
45	Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunology, Immunotherapy, 2007, 56, 839-847.	2.0	28
46	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology, 2016, 136, 994-1001.	0.3	27
47	An immunodominant SSX-2â€"derived epitope recognized by CD4+ T cells in association with HLA-DR. Journal of Clinical Investigation, 2004, 113, 1225-1233.	3.9	27
48	Decreased Binding of Peptides-MHC Class I (pMHC) Multimeric Complexes to CD8 Affects Their Binding Avidity for the TCR But Does Not Significantly Impact on pMHC/TCR Dissociation Rate. Journal of Immunology, 2003, 170, 5110-5117.	0.4	24
49	Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. Cancer Immunity, 2008, 8, 11.	3.2	24
50	Lentivector immunization induces tumor antigenâ€specific Bâ€„and T cell responses <i>in vivo</i>. European Journal of Immunology, 2008, 38, 1867-1876.	1.6	22
51	CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg. Cancer Immunology Research, 2013, 1, 303-308.	1.6	21
52	Anti-TNF, a magic bullet in cancer immunotherapy?. , 2019, 7, 303.		21
53	CD4+ T Cell Responses to SSX-4 in Melanoma Patients. Journal of Immunology, 2005, 174, 5092-5099.	0.4	20
54	Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors. Journal of Immunotherapy, 2009, 32, 161-168.	1.2	20

#	Article	IF	Citations
55	Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy. PLoS ONE, 2011, 6, e21129.	1.1	20
56	Assessment of MAGE-A Expression in Resected Nonâ€"Small Cell Lung Cancer in Relation to Clinicopathologic Features and Mutational Status of <i>EGFR</i> and <i>KRAS</i>. Cancer Immunology Research, 2014, 2, 943-948.	1.6	20
57	Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clinical Immunology, 2006, 121, 54-62.	1.4	19
58	Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire. Clinical Cancer Research, 2009, 15, 4467-4474.	3.2	19
59	Radiotherapy in the Era of ImmunotherapyÂWith a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?. Frontiers in Oncology, 2021, 11, 662236.	1.3	19
60	HLA Class Iâ€"Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine. Clinical Cancer Research, 2009, 15, 299-306.	3.2	18
61	Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells. Journal of Immunology, 2004, 172, 7206-7211.	0.4	17
62	Distinct but overlapping T helper epitopes in the 37â€"58 region of SSX-2. Clinical Immunology, 2005, 114, 70-78.	1.4	17
63	Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. Clinical Immunology, 2005, 117, 161-167.	1.4	17
64	Colon-specific immune microenvironment regulates cancer progression versus rejection. OncoImmunology, 2020, 9, 1790125.	2.1	17
65	Circulating CD14^{high}CD16^{low}intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. , 2020, 8, e000472.		17
66	Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clinical Immunology, 2007, 122, 163-172.	1.4	16
67	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. Cancer Immunology Research, 2020, 8, 869-882.	1.6	16
68	Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clinical Immunology, 2005, 117, 24-30.	1.4	15
69	An immunodominant SSX-2â€"derived epitope recognized by CD4+ T cells in association with HLA-DR. Journal of Clinical Investigation, 2004, 113, 1225-1233.	3.9	15
70	A Structure-based Approach to Designing Non-natural Peptides That Can Activate Anti-melanoma Cytotoxic T Cells. Journal of Biological Chemistry, 1999, 274, 10227-10234.	1.6	13
71	Single-Cell Virtual Cytometer allows user-friendly and versatile analysis and visualization of multimodal single cell RNAseq datasets. NAR Genomics and Bioinformatics, 2020, 2, lqaa025.	1.5	13
72	SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immunity, 2003, 3, 13.	3.2	13

#	Article	IF	Citations
73	Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogs. , 1998, 12, 557-564.		12
74	NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment. PLoS ONE, 2011, 6, e22845.	1.1	12
75	Comment on â€œHelios+ and Heliosâˆ' Cells Coexist within the Natural FOXP3+ T Regulatory Cell Subset in Humansâ€. Journal of Immunology, 2013, 190, 4439-4440.	0.4	12
76	Phased differentiation of Î³Î´ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers. OncoImmunology, 2021, 10, 1939518.	2.1	11
77	Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity. PLoS ONE, 2015, 10, e0145788.	1.1	11
78	Using Modified Antigenic Sequences to Develop Cancer Vaccines: Are We Losing the Focus?. PLoS Medicine, 2004, 1, e26.	3.9	10
79	A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. Clinical Immunology, 2006, 118, 188-194.	1.4	10
80	Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers. Clinical Cancer Research, 2010, 16, 4607-4615.	3.2	10
81	Generation of Th17 from human naive CD4+ T cells preferentially occurs from FOXP3+ Tregs upon costimulation via CD28 or CD5. Blood, 2012, 119, 4810-4812.	0.6	10
82	Assessment of CD4+Â T cells specific for the tumor antigen SSX-1 in cancer-free individuals. Cancer Immunology, Immunotherapy, 2007, 56, 1183-1192.	2.0	8
83	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers, 2020, 12, 1761.	1.7	8
84	MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. Haematologica, 2013, 98, 316-322.	1.7	7
85	A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia. Blood, 2003, 101, 4643-4644.	0.6	6
86	Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers. Annals of Oncology, 2011, 22, 986-987.	0.6	6
87	Tinkering with Nature: The Tale of Optimizing Peptide Based Cancer Vaccines. , 2005, 123, 267-291.		5
88	CD4+T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs. OncoImmunology, 2015, 4, e946370.	2.1	3
89	Comment on â€œDifferentiation of IL-17â€"Producing Effector and Regulatory Human T Cells from Lineage-Committed Naive Precursorsâ€. Journal of Immunology, 2014, 193, 3181-3181.	0.4	1
90	Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer. OncoImmunology, 2016, 5, e947175.	2.1	1

#	Article	IF	Citations
91	Lack of tumor recognition by hTERT peptide 540â€“548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. , 2001, 31, 2642.		1
92	Liens entre gÃ©nÃ©tique et immunologie : mutations et antigÃ¨nes. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 67-79.	0.0	0